SciELO - Scientific Electronic Library Online

vol.44 issue2Immune System, SARS-CoV-2 Infection and Development of COVID-19Combined Treatment in Cutaneous Leishmaniasis with Therapeutic Failure author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • Have no similar articlesSimilars in SciELO


Gaceta Médica Boliviana

Print version ISSN 1012-2966On-line version ISSN 2227-3662


HUANCA HUANCA, María Luz; CALDERON LOPEZ, Maria Elena; ROJAS CABRERA, Ernesto  and  SAAVEDRA BORDA, Carmen Rocío. Liposomal Amphotericin B, Pediatric Treatment of Cutaneous Leishmaniasis with Therapeutic Failure. Gac Med Bol [online]. 2021, vol.44, n.2, pp.254-259. ISSN 1012-2966.

The cutaneous leishmaniasis in Bolivia is less frequent in children. Its presence probably responds to the domestication of the vector in areas of human settlements. Amphotericin B is indicated for the treatment of leishmaniasis in adults, without response to pentavalent antimonials or without a clinical cure for ulcers. The objective of this series of cases is to share experiences of the use of liposomal amphotericin B in paediatric patients with cutaneous leishmaniasis and therapeutic failure of antimonials. Six patients with these characteristics admitted to the Infectology service of the Manuel Asencio Villarroel paediatric hospital, received liposomal Amphotericin B, 2 to 3 mg / kg weight day, in a mean period of 18 days. Progressive remission of the ulcers was observed during treatment and complete healing at three months of post-treatment. None had adverse effects, and the kidney and liver biochemical tests were within normal values.

Keywords : leishmaniasis cutaneous; amphotericin B; eficacy; treatment outcome.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )